Weight-loss drug developer Metsera valued at $2.68 bln as shares jumped in market debut
Shares of weight-loss drug developer Metsera jumped nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture ...
About Half of Americans Approve of Using Weight-Loss Drugs to Treat Obesity, AP-NORC Poll Finds
A new poll from The Associated Press-NORC Center for Public Affairs Research shows about half of U.S. adults believe it is a ...
Half of Americans Support Weight-Loss Drugs Like Ozempic for Obesity, Poll
Cost is a major obstacle for many. The drugs can be expensive without insurance, with out-of-pocket expenses reaching ...
The high cost of weight loss: How patients are fighting for access to breakthrough medications
CBS News Miami investigates the financial hurdles surrounding these medications and explores alternatives that may offer a ...
Why Weight-Loss Drugs Could Be Game-Changers for Your Investment Portfolio
Weight-loss drugs are transforming health care and Wall Street, but exciting prospects don’t necessarily mean a company is a good investment.
Weight-loss drug developer Metsera raises $275 million in US IPO
Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...
How GLP-1 medications are transforming diabetes and weight loss treatment
Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...
Researchers Present Ozempic Alternatives—Without Sickening GI Side Effects
These compounds take a different approach to weight loss than existing medications, which can cause nausea, vomiting and ...
Ozempic May Protect Against Alzheimer’s
One recent analysis found that, over the course of three years, people taking semaglutide (the compound in Ozempic and the weight loss drug Wegovy) were about 40 to 70 percent less likely to be ...